clinical trial · NCT05456880
BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease
Sickle Cell DiseaseBEAM-101
brief summary
This is an open-label, single-arm, multicenter, Phase 1/2 study evaluating the safety and efficacy of the administration of autologous base edited CD34+ HSPCs (BEAM-101) in patients with severe SCD
started
Aug 30, 2022
primary completion
Feb 1, 2028
completion
Feb 1, 2028
last updated
Dec 16, 2025
official title
A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients With Sickle Cell Disease and Severe Vaso-Occlusive Crises (Beacon Trial)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol